Bortezomib Boom Benefits Stada But Pemetrexed Position Proves Perplexing
• By Aidan Fry
Introducing ready-to-use vials of bortezomib in 14 European countries helped Stada to post 11% turnover growth in the first half of this year • Source: Shutterstock
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
